Scientific Article
previous document  unige:103449  next document
add to browser collection

TLR7 agonist in combination with Salmonella as an effective antimelanoma immunotherapy

Vola, Magdalena
Mónaco, Amy
Rimsky, Geraldine
Agorio, Caroline Isabel
Chabalgoity, José Alejandro
Moreno, María
Published in Immunotherapy. 2018
Abstract AIM: We evaluated a novel approach combining the use of attenuated Salmonella immunotherapy with a Toll-like receptor agonist, imiquimod, in B16F1 melanoma-bearing mice. MATERIALS & METHODS: B16F1 melanoma-bearing mice were daily treated with topical imiquimod in combination with one intratumoral injection of attenuated Salmonella enterica serovar Typhimurium LVR01. RESULTS: The combined therapy resulted in retarded tumor growth and prolonged survival. Combination treatment led to an enhancement in the expression of pro-inflammatory cytokines and chemokines in the tumor microenvironment, with a Th1-skewed profile, resulting in a broad antitumor response. The induced immunity was effective in controlling the occurrence of metastasis. CONCLUSION: Salmonella LVR01 immunotherapy in combination with imiquimod is a novel approach that could be considered as an effective antimelanoma therapy.
Keywords SalmonellaExperimental modelImiquimodImmunotherapyMelanoma
PMID: 29562809
Full text
This document has no fulltext available yet, but you can contact its author by using the form below.
(ISO format)
VOLA, Magdalena et al. TLR7 agonist in combination with Salmonella as an effective antimelanoma immunotherapy. In: Immunotherapy, 2018. doi: 10.2217/imt-2017-0188

221 hits

0 download


Deposited on : 2018-04-10

Export document
Format :
Citation style :